Life Sciences Investment Opportunities
Curated deal flow from the SoCal OASIS® innovation ecosystem
The SoCal OASIS® initiative supports the commercialization of high-impact technologies emerging from the University of California, Riverside and the broader Inland Southern California innovation ecosystem.
Below is a curated selection of life sciences companies currently raising capital. These opportunities span preclinical through pre-FDA stages and represent therapeutic innovation across neurology, ophthalmology, and metabolic disease.
Companies listed have been supported through the Office of Technology Partnerships and are actively engaging with investors aligned with translational science and clinical milestone-driven growth.
Cadenza Bio
Cadenza Bio is developing first-in-class, selective Estrogen Receptor Beta (ERβ) small molecules to treat demyelinating and inflammatory diseases. Their lead program targets Multiple Sclerosis (MS) with a dual-mechanism drug that promotes remyelination and reduces neuroinflammation. They also have pipeline assets for Endometriosis and Menopause.
- Stage: Preclinical (Lead candidate CAD-102 is in IND-enabling studies; anticipated Phase 1 start H1 2027).
- Raise: Seeking $20M Series A (to deliver Phase 1 data in MS patients and reach IND in Endometriosis).
Eye Guardian
Eye Guardian is developing an AI-powered, non-contact smart eyewear system for Glaucoma care. The device allows for continuous, daily monitoring of Intraocular Pressure (IOP) between clinic visits, addressing the critical data gap in current glaucoma management to prevent blindness.
- Stage: Seed / Development (Completed pre-pivotal trials on 10 humans; currently finalizing device for clinical trials and FDA approval).
- Raise: Seeking $6.4M Seed Round.
SymbioCellTech
SymbioCellTech is a regenerative medicine company developing "Neo-Islets," a stem cell-enabled biotherapy designed to cure Type 1 Diabetes without the need for chronic immunosuppression. The technology aggregates insulin-producing cells with immune-shielding stem cells to restore natural glycemic control.
- Stage: Late Preclinical (Preparing for IND-enabling studies; plan to initiate Phase 1/2 First-in-Human trials within 12-14 months).
- Raise: Seeking $7M (to fund IND-enabling studies and initial operations for the next 15 months).
Your Investment Liaison
Investor Inquiries
For access to company decks, data rooms, or introductions to founding teams, please contact:
Scott Brovsky
Associate Director, Regional Engagement
Entrepreneurial Proof-of-Concept and Innovation Center (EPIC)
scott.brovsky@ucr.edu
Confidential information provided for informational purposes only. This content does not constitute an offer to sell or a solicitation to buy securities. Investment opportunities are available only to qualified investors.